About The Study: Pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation burden at 6 months, with substantial improvements in symptoms and quality of life, compared with a sham procedure.
About The Study: Pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation burden at 6 months, with substantial improvements in symptoms and quality of life, compared with a sham procedure.
Corresponding Authors: To contact the corresponding authors, email Rick A. Veasey, MD, (rick.veasey@nhs.net) and Rajdip Dulai, MBBS, (rajdip.dulai.21@ucl.ac.uk)
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jama.2024.17921)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the European Society of Cardiology Congress 2024.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA
Cite Scienmag News
Reid Dalton. (September 2, 2024). Pulmonary vein isolation vs sham intervention in symptomatic atrial fibrillation. Scienmag. https://scienmag.com/pulmonary-vein-isolation-vs-sham-intervention-in-symptomatic-atrial-fibrillation/
Reid Dalton. "Pulmonary vein isolation vs sham intervention in symptomatic atrial fibrillation." Scienmag, 2 September 2024, https://scienmag.com/pulmonary-vein-isolation-vs-sham-intervention-in-symptomatic-atrial-fibrillation/. Accessed 4 September 2026.
Reid Dalton. "Pulmonary vein isolation vs sham intervention in symptomatic atrial fibrillation." Scienmag. September 2, 2024. https://scienmag.com/pulmonary-vein-isolation-vs-sham-intervention-in-symptomatic-atrial-fibrillation/
